6MK.DE - Merck & Co., Inc.

Frankfurt - Frankfurt Delayed price. Currency in EUR
53.703
-0.332 (-0.614%)
At close: 11:30AM CEST
Stock chart is not supported by your current browser
Previous close54.035
Open53.763
Bid53.979 x 100000
Ask54.051 x 100000
Day's range53.510 - 53.882
52-week range53.060 - 63.340
Volume809
Avg. volume2,578
Market cap146.1B
BetaN/A
PE ratio (TTM)29.08
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters7 hours ago

    Merck cyber attack may cost insurers $275 million - Verisk's PCS

    Insurers could pay $275 million (209.06 million pounds) to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.

  • Merck cyber attack may cost insurers $275 million: Verisk's PCS
    Reuters7 hours ago

    Merck cyber attack may cost insurers $275 million: Verisk's PCS

    Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services unit. ...

  • Barrons.comyesterday

    Merck: Is Keytruda a $16B Drug?

     Is Wall Street underestimating Keytruda? Shares of Merck& Co. ( MRK) popped today after Citigroup’s Andrew Baum upgraded the drug maker to Buy from Neutral, and hiked his price target from $65 a share to $72 a share, citing heightened expectations for the blockbuster cancer drug. It’s been a volatile 2017 for Merck.

  • Market Realist2 days ago

    Behind Merck’s Performance in 3Q17

    MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.

  • The Wall Street Journal8 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • Market Realist15 days ago

    Changes in Eli Lilly’s Valuation

    On September 28, 2017, Eli Lilly was trading at a forward PE multiple of ~18.7x compared to the industry average of ~16.6x.

  • The Wall Street Journal15 days ago

    [$$] LBO Profile: GHIF Uses PE Model to Tackle Global Health Challenges

    Global Healthcare Investment Advisors LLC wants to generate more than just healthy financial returns with its deals. The New York-based firm, which does business as the Global Health Investment Fund, also ...

  • Bloomberg16 days ago

    The Hepatitis Drug Market Is Worse Than Wall Street Realizes

    Analysts haven't gotten the message, but some drugmakers have.

  • The Wall Street Journal20 days ago

    [$$] Merck Abandons New Hepatitis C Drugs Amid Crowded Market

    Merck & Co. is halting development of new hepatitis C treatments after reviewing their effectiveness and determining an abundance of treatments were already available.

  • Market Realist21 days ago

    Must-Know Changes to Bristol-Myers Squibb’s Valuation

    Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.

  • MarketWatch21 days ago

    Merck discontinues development program for a Hep-C treatment

    Merck & Co. said Friday it would discontinue the development of the investigational combination regimens MK-3682B and MK-3682C for the treatment of chronic hepatitis C, after a review of available Phase ...

  • Reuters - UK Focuslast month

    Merck's immunotherapy, chemo mix shows extended lung cancer gains

    Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time.

  • Reuters - UK Focus2 months ago

    AstraZeneca aims to offset drug setback at big cancer congress

    After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease ...

  • Charlottesville resignation: Chief executive encapsulates American Dream
    Sky News2 months ago

    Charlottesville resignation: Chief executive encapsulates American Dream

    Kenneth Frazier, the Merck (LSE: 0O14.L - news) chief executive who has resigned from President Trump's Manufacturing Council, has an inspiring story that encapsulates the American Dream. Mr Frazier's grandfather was a South Carolina sharecropper, working in the system set up following the American Civil War under which landowners allowed tenant farmers to use their land in exchange for a portion of the crop.

  • Merck, Under Armour CEOs quit Trump advisory panel over rally response
    AFP2 months ago

    Merck, Under Armour CEOs quit Trump advisory panel over rally response

    Merck CEO Kenneth Frazier is seen here with President Donald Trump at a White House event in July.

  • Reuters - UK Focus2 months ago

    Merck CEO resigns from Trump council over Charlottesville

    Merck (Jakarta: 28586808.JK - news) & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, saying he was taking a stand against intolerance and extremism. Trump denounced neo-Nazis and the Ku Klux Klan as criminals and thugs on Monday, bowing to mounting political pressure after initially saying many sides were to blame after a white-nationalist rally turned deadly in Virginia. Frazier, who is African-American, is the only CEO so far to leave one of Trump's advisory councils because of his reaction to the violence in Virginia.

  • Reuters - UK Focus3 months ago

    Merck says cyber attack halted production, will hurt profits

    NEW YORK/LAS VEGAS, July 28 (Reuters) - Drug and vaccine maker Merck (Jakarta: 28586808.JK - news) & Co Inc said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June, halting production of its drugs, which will hurt its profits for the rest of the year. The company said it does not yet understand the full magnitude of the impact as it is in the process of restoring manufacturing operations. Merck (LSE: 0O14.L - news) said it was confident that it will be able to maintain a continuous supply of its top-selling and life-saving drugs, including cancer drug Keytruda, diabetes drug Januvia and hepatitis C drug Zepatier.

  • Reuters - UK Focus3 months ago

    Bristol-Myers shares slump after failed AstraZeneca drug trial

    Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc (NYSE: AZN - news) would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen. AstraZeneca's Mystic study, released Thursday, looked at a combination of immune system-boosting drugs to treat non-small cell lung cancer (NSCLC). Bristol-Myers is studying a similar combination of its two top drugs in the same therapy class, Opdivo and Yervoy.

  • Reuters - UK Focus3 months ago

    AstraZeneca lung cancer failure sparks 16 percent share fall

    AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares on Thursday. The so-called Mystic study was the industry's most anticipated clinical experiment this year and the news saw the shares fall 16 percent, wiping some $14 billion off AstraZeneca's value.

  • AstraZeneca, Merck strike key cancer drugs partnership
    AFP3 months ago

    AstraZeneca, Merck strike key cancer drugs partnership

    A nurse prepares chemotherapy drugs

  • Reuters - UK Focus4 months ago

    Threat to HIV business spooks GlaxoSmithKline shares

    The threat of slowing demand and new competition in GlaxoSmithKline (Other OTC: GLAXF - news) 's flagship HIV drug business unnerved investors in Britain's biggest drugmaker on Wednesday, sending its shares down as much as 1.8 percent. GSK pared losses to 0.8 percent by 1220 GMT but remained among the top losers in London's FTSE-100 index after Citigroup (Swiss: C-USD.SW - news) downgraded the stock to neutral from buy and cut earnings forecasts by up to 9 percent. HIV medicines, which GSK sells through its ViiV Healthcare unit, have been star performers in recent years and new CEO Emma Walmsley said in April that the "HIV portfolio continues to go from strength to strength".

  • Reuters - UK Focus4 months ago

    Cyber attack sweeps globe, researchers see 'WannaCry' link

    MOSCOW/KIEV/WASHINGTON, June 27 (Reuters) - A major global cyber attack on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware that last month infected more than 300,000 computers. The rapidly spreading cyber extortion campaign underscored growing concerns that businesses have failed to secure their networks from increasingly aggressive hackers, who have shown they are capable of shutting down critical infrastructure and crippling corporate and government networks.

  • Reuters - UK Focus5 months ago

    UK competition watchdog accuses Merck of obstructing biosimilars

    Britain's competition watchdog has accused Merck & Co (Swiss: MRK-USD.SW - news) of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies. The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found the U.S. company's European unit, Merck Sharp & Dohme, had abused its dominant position through the scheme, opening it up to potential financial penalties.

  • Reuters - UK Focus5 months ago

    How AstraZeneca cancer drug forecasts are set to rise

    Sales forecasts for AstraZeneca's all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer last week. ...

  • Reuters - UK Focus5 months ago

    AstraZeneca shares surge after key drug shows promise in lung cancer trial

    A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business. The trial results are an unexpectedly early boost for the product, known commercially as Imfinzi, which the company hopes will become a blockbuster drug with sales in the billions of dollars. It sets AstraZeneca apart from rivals Merck (LSE: 0O14.L - news) and Roche, whose equivalent drugs are years behind in the race for similar treatments against lung cancer.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes